211 related articles for article (PubMed ID: 28249663)
1. Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer?
Ravulapati S; Leung C; Poddar N; Tu Y
Am J Med; 2017 May; 130(5):e207-e208. PubMed ID: 28249663
[No Abstract] [Full Text] [Related]
2. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
Tran DC; Colevas AD; Chang AL
JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
[No Abstract] [Full Text] [Related]
3. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
[No Abstract] [Full Text] [Related]
4. Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.
Ali SA; Arman HE; Patel AA; Birhiray RE
JCO Oncol Pract; 2020 Mar; 16(3):137-138. PubMed ID: 31770056
[No Abstract] [Full Text] [Related]
5. Massive Periocular Squamous Cell Carcinoma With Response to Pembrolizumab (Keytruda).
Conger JR; Grob SR; Tao J
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e127. PubMed ID: 30925541
[No Abstract] [Full Text] [Related]
6. GQ1b-Seronegative Miller Fisher Syndrome Associated With Pembrolizumab.
Green KE; Levine AM; Ward JH; Kaufman DI
J Neuroophthalmol; 2019 Sep; 39(3):394-396. PubMed ID: 30801443
[No Abstract] [Full Text] [Related]
7. Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma.
Vaccaro M; Bertino L; Santarpia M; Altavilla G; Cannavò SP
Dermatol Ther; 2020 Nov; 33(6):e14417. PubMed ID: 33068047
[No Abstract] [Full Text] [Related]
8. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
Hanania HL; Lewis DJ
Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
[No Abstract] [Full Text] [Related]
9. Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report.
Nelson R; Luu L; Silberstein P; Velagapudi M; Huerter C
Int J Dermatol; 2021 Feb; 60(2):233-235. PubMed ID: 32955136
[No Abstract] [Full Text] [Related]
10. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Reimer A; Lu S; He Y; Bruckner-Tuderman L; Technau-Hafsi K; Meiss F; Has C; von Bubnoff D
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):e1-e3. PubMed ID: 31374134
[No Abstract] [Full Text] [Related]
11. Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.
Di Prima A; Botticelli A; Scalzulli E; Colafigli G; Pepe S; Lisi C; Marchetti P; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 Aug; 100(8):2117-2119. PubMed ID: 32856142
[No Abstract] [Full Text] [Related]
12. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Venkatesh S; Al-Haseni A; Sahni D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
[TBL] [Abstract][Full Text] [Related]
13. Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma.
Corbett M; Tohani S; Ramli R; O'Duffy F
JAMA Otolaryngol Head Neck Surg; 2024 Jun; 150(6):524-525. PubMed ID: 38602669
[TBL] [Abstract][Full Text] [Related]
14. Cemiplimab removed from reimbursable drugs in France.
Pham F; Reynaud B; Favier B; Darnis S; Amini-Adle M
Eur J Cancer; 2021 May; 149():11-13. PubMed ID: 33812142
[No Abstract] [Full Text] [Related]
15. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
16. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
[No Abstract] [Full Text] [Related]
17. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma.
Degache E; Crochet J; Simon N; Tardieu M; Trabelsi S; Moncourier M; Templier I; Foroni L; Lemoigne A; Pinel N; Gil H; Bouillet L; Leccia MT; Charles J
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e257-e258. PubMed ID: 28557105
[No Abstract] [Full Text] [Related]
18. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia : a case series and literature review.
Eglmeier J; Debus D; Schultz ES
Eur J Dermatol; 2020 Feb; 30(1):69-71. PubMed ID: 32250263
[No Abstract] [Full Text] [Related]
19. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
[No Abstract] [Full Text] [Related]
20. Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab.
Berliner JG; Schulman JM; Lazarova Z; Olasz E; Arron ST
Dermatol Surg; 2019 Feb; 45(2):313-316. PubMed ID: 29957662
[No Abstract] [Full Text] [Related]
[Next] [New Search]